The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women
Abstract
OBJECTIVE. Prophylactic vaccination of 16- to 23-year-old females with a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been shown to prevent type-specific human papillomavirus infection and associated clinical disease. We conducted a noninferiority immunogenicity study to bridge the efficacy findings in young women to preadolescent and adolescent girls and boys, who represent a primary target for human papillomavirus vaccination. METHODS. We enrolled 506 girls and 510 boys (10–15 years of age) and 513 females (16–23 years of age). Participants were vaccinated on day 1, at month 2, and at month 6, and serology testing was performed on day 1 and at months 3 and 7 on blinded samples. Neutralizing antibody concentrations were determined using type-specific immunoassays and summarized as geometric mean titers and seroconversion rates. Vaccine tolerability also was assessed. RESULTS. By month 7, seroconversion rates were ≥99% for all 4 human papillomavirus types in each group. By month 7, compared with women, anti–human papilloma virus geometric mean titers in girls or boys were noninferior and were 1.7- to 2.7-fold higher. Most (>97%) injection-site adverse events were mild to moderate in intensity. Significantly more boys (13.8%) and girls (12.8%) than women (7.3%) reported fevers ≥37.8°C within 5 days of vaccination. Most (96.4%) fevers were mild (<39°C). CONCLUSIONS. Noninferior immunogenic responses to all 4 human papillomavirus types in the quadrivalent vaccine permit the bridging of efficacy data that were generated in young women to girls. The results in boys lend support for the implementation of gender-neutral human papillomavirus vaccination programs. This vaccine generally was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Lavanchy, D. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00487.x · Cited by 2,642
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Self-citationVilla, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Self-citationSexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000
Weinstock, H., Berman, S., & Cates, W. (2004) · Perspectives on Sexual and Reproductive Health · doi:10.1363/3600604 · Cited by 1,258
Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000
Weinstock, H., Berman, S., & Cates, W. (2004) · Perspectives on Sexual and Reproductive Health · doi:10.1111/j.1931-2393.2004.tb00002.x · Cited by 1,153
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
The epidemiology of human papillomavirus infections
Baseman, J. G., & Koutsky, L. A. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.12.008 · Cited by 955
Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of Causality
Bosch, F. X., & de Sanjose, S. (2003) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003479 · Cited by 826
Woodman, C. B., Collins, S., Winter, H., Bailey, A., Ellis, J., Prior, P., Yates, M., Rollason, T. P., & Young, L. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04956-4 · Cited by 822
Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners
Castellsagué, X., Bosch, F. X., Muñoz, N., Meijer, C. J. L. M., Shah, K. V., de Sanjosé, S., Eluf-Neto, J., Ngelangel, C. A., Chichareon, S., Smith, J. S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011688 · Cited by 804
Nobbenhuis, M. A., Walboomers, J. M., Helmerhorst, T. J., Rozendaal, L., Remmink, A. J., Risse, E. K., van der Linden, H. C., Voorhorst, F. J., Kenemans, P., & Meijer, C. J. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12490-x · Cited by 685
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., & Franco, E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh104 · Cited by 539
Youth Risk Behavior Surveillance--United States, 2003: (307132005-001)
Grunbaum, J. A., Kann, L., Kinchen, S., Ross, J., Hawkins, J., & Lowry, R. (2004) · PsycEXTRA Dataset · doi:10.1037/e307132005-001 · Cited by 477
Mao, C., Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Wiley, D. J., Alvarez, F. B., Bautista, O. M., Jansen, K. U., & Barr, E. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000192397.41191.fb · Cited by 451
Self-citationExternal Genital Warts: Diagnosis, Treatment, and Prevention
Wiley, D. J., Douglas, J., Beutner, K., Cox, T., Fife, K., Moscicki, A., & Fukumoto, L. (2002) · Clinical Infectious Diseases · doi:10.1086/342109 · Cited by 354
Human Papillomavirus Vaccine Acceptability Among Parents of 10- to 15-Year-Old Adolescents
Davis, K., Dickman, E. D., Ferris, D., & Dias, J. K. (2004) · Journal of Lower Genital Tract Disease · doi:10.1097/00128360-200407000-00005 · Cited by 348
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
Kulasingam, S. L. (2003) · JAMA · doi:10.1001/jama.290.6.781 · Cited by 337
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Sanders, G. D., & Taira, A. V. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0901.020168 · Cited by 310
Opalka, D., Lachman, C. E., MacMullen, S. A., Jansen, K. U., Smith, J. F., Chirmule, N., & Esser, M. T. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.1.108-115.2003 · Cited by 276
Deacon, J. M., Evans, C. D., Yule, R., Desai, M., Binns, W., Taylor, C., & Peto, J. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1523 · Cited by 263
Parental acceptance of the human papillomavirus vaccine
Olshen, E., Woods, E. R., Austin, S. B., Luskin, M., & Bauchner, H. (2005) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2005.05.016 · Cited by 244
Dias, D., Van Doren, J., Schlottmann, S., Kelly, S., Puchalski, D., Ruiz, W., Boerckel, P., Kessler, J., Antonello, J. M., Green, T., et al. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.8.959-969.2005 · Cited by 241
Self-citationThe Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine
Hughes, J. P., Garnett, G. P., & Koutsky, L. (2002) · Epidemiology · doi:10.1097/00001648-200211000-00006 · Cited by 230
Rousseau, M., Pereira, J. S., Prado, J. C. M., Villa, L. L., Rohan, T. E., & Franco, E. L. (2001) · The Journal of Infectious Diseases · doi:10.1086/324579 · Cited by 228
Insinga, R. P., Dasbach, E. J., & Myers, E. R. (2003) · Clinical Infectious Diseases · doi:10.1086/375074 · Cited by 216
A Study of 10 296 Pediatric and Adolescent Papanicolaou Smear Diagnoses in Northern New England
Mount, S. L., & Papillo, J. L. (1999) · PEDIATRICS · doi:10.1542/peds.103.3.539 · Cited by 136
Management of anogenital warts (condylomata acuminata).
von Krogh, G. (2001) · PubMed · Cited by 105
A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine
Ault, K. A., Giuliano, A. R., Edwards, R. P., Tamms, G. M., Kim, L.-L., Smith, J. F., Jansen, K. U., Allende, M. C., Taddeo, F. J., Skulsky, D., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.02.020 · Cited by 99
Self-citationBöttiger, M., & Forsgren, M. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00068-6 · Cited by 70
A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults
Marsano, L. S., West, D. J., Chan, I. S. F., Hesley, T. M., Cox, J., Hackworth, V., & Greenberg, R. N. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00233-8 · Cited by 64
Poland, G. A., Jacobson, R. M., Koutsky, L. A., Tamms, G. M., Railkar, R. A., Smith, J. F., Bryan, J. T., Cavanaugh, P. F., Jansen, K. U., & Barr, E. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.5.601 · Cited by 60
Self-citation
Cited by
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Self-citationMarkowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007) · PsycEXTRA Dataset · doi:10.1037/e601292007-001 · Cited by 1,882
Nooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 869
Holman, D. M., Benard, V., Roland, K. B., Watson, M., Liddon, N., & Stokley, S. (2014) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2013.2752 · Cited by 863
Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Paavonen, J., Iversen, O.-E., Olsson, S.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603469 · Cited by 806
Self-citation
Metadata
- Authors
- Block, S. L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K. E. D., Marchant, C. D., Castellsagué, X., Rusche, S. A., Lukac, S., Bryan, J. T., Cavanaugh, P. F., Reisinger, K. S., & for the Protocol 016 Study Group
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2006-11-01
- Volume
- 118
- Issue
- 5
- Pages
- 2135-2145
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2073486485
- Cited by
- 484
- References
- 33
- FWCI
- 35.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.